Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg, a generic version of Ranexa®1 Extended-Release Tablets, 500 mg and 1,000 mg, of Gilead Sciences, Inc.
According to IQVIATM sales data for the 12 month period ending May 2019, the Ranexa® ExtendedRelease Tablets, 500 mg and 1,000 mg market2 achieved annual sales of approximately $929.0 million*.
Glenmark's current portfolio consists of 158 products authorized for distribution in the U.S. marketplace and 57 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.448 as compared to the previous close of Rs. 436.75. The total number of shares traded during the day was 114830 in over 3291 trades.
The stock hit an intraday high of Rs. 452.35 and intraday low of 436.8. The net turnover during the day was Rs. 51489543.
1All brand names and trademarks are the property of their respective owners.
2Market includes brand and all available therapeutic equivalents
*IQVIATM National Sales Perspectives: Retail & Non-Retail, May 2019